Transplant center directory

St. Louis University Cancer Center Blood & Marrow Transplant Program performs a wide range of transplants including autologous, related and unrelated allogeneic, haploidentical, and umbilical cord blood transplants for a range of disorders including lymphomas, multiple myeloma, amyloidosis, leukemias, myelodysplastic syndromes and myeloproliferative disorders, testicular cancer & non-malignant hematological disorders such as aplastic anemia. We also perform Chimeric Antigen T cell (CAR T-cell) therapy for lymphomas and leukemias.

This center has been performing allogeneic transplants since 1991 and has been an NMDP/Be The Match transplant center since February 1993.

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 77 patients.

The actual 1-year survival of these patients is 63.6%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 62.4% and 81.7%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.